Stock LYRA LYRA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Lyra Therapeutics, Inc.

Equities

LYRA

US55234L1052

Real-time Estimate Cboe BZX
Other stock markets
 12:58:43 2024-06-10 pm EDT 		5-day change 1st Jan Change
0.311 USD -2.93% Intraday chart for Lyra Therapeutics, Inc. -4.56% -94.08%
May. 21 Lyra Therapeutics Reduces Workforce to Extend Cash Runway MT
May. 21 Lyra Therapeutics, Inc. Announces Termination of John E. Bishop as Chief Technology Officer, Effective on or About June 20, 2024 CI

Evolution of the average Target Price on Lyra Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

f12fe6f672dba97355f2f5ab9f92f8.3fkH3UgBpDz1Y-BsY3Pa5fnGD-5hrjrFgisaGhBz9Og.tIoyjhdr8FWQUbAJOhC-h4iWW8MCxQiwz2o3b1Res5C2nXGNHnjSEb0QuQ~04ff6cc32e8f4bcd942a3ef6c22594cd

Analyst Recommendations on Lyra Therapeutics, Inc.

Jefferies Downgrades Lyra Therapeutics to Hold, Price Target at $0.50 MT
HC Wainwright Downgrades Lyra Therapeutics to Neutral From Buy MT
BTIG Assumes Lyra Therapeutics at Buy With $15 Price Target MT
BofA Securities Increases Price Target on Lyra Therapeutics to $15 From $13, Maintains Buy Rating MT
HC Wainwright Starts Lyra Therapeutics at Buy With $12 Price Target MT
BTIG Adjusts Price Target on Lyra Therapeutics to $20 From $24, Maintains Buy Rating MT
Cantor Fitzgerald Starts Lyra Therapeutics at Overweight With $15 Price Target MT
LYRA THERAPEUTICS : BofA securities Adjusts Lyra Therapeutics PT to $26 From $19, Maintains Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
0.3204 USD
Average target price
4.5 USD
Spread / Average Target
+1,304.49%
High Price Target
11 USD
Spread / Highest target
+3,333.21%
Low Price Target
0.5 USD
Spread / Lowest Target
+56.05%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Lyra Therapeutics, Inc.

HC Wainwright
Jefferies & Co.
BTIG
BofA Securities
Cantor Fitzgerald

Ratings for Lyra Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. LYRA Stock
  4. Consensus Lyra Therapeutics, Inc.